BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 12927315)

  • 1. Modification of serum IGF-I, IGFBPs and SHBG levels by different HRT regimens.
    Biglia N; Ambroggio S; Ponzone R; Sgro L; Ujcic E; Dato FA; Sismondi P
    Maturitas; 2003 Aug; 45(4):283-91. PubMed ID: 12927315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral 17beta-estradiol and sequential progesterone in menopause: effects on insulin-like growth factors and their binding proteins.
    Mozzanega B; Babbo GL; Salmaso L; De Toni R; Schiavo A; Mioni R; de Kreutzenberg SV
    Gynecol Endocrinol; 2007 Jan; 23(1):50-7. PubMed ID: 17484513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positive effects on cardiovascular and breast metabolic markers of oral estradiol and dydrogesterone in comparison with transdermal estradiol and norethisterone acetate.
    Campagnoli C; Colombo P; De Aloysio D; Gambacciani M; Grazioli I; Nappi C; Serra GB; Genazzani AR
    Maturitas; 2002 Apr; 41(4):299-311. PubMed ID: 12034517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of hormone replacement therapy on insulin-like growth factor (IGF)-I, IGF-II and IGF binding protein (IGFBP)-1 to IGFBP-4: implications for cardiovascular risk.
    Heald A; Kaushal K; Anderson S; Redpath M; Durrington PN; Selby PL; Gibson MJ
    Gynecol Endocrinol; 2005 Mar; 20(3):176-82. PubMed ID: 16019358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of hormonal replacement therapy on plasma sex hormone-binding globulin, androgen and insulin-like growth factor-1 levels in postmenopausal women.
    Stomati M; Hartmann B; Spinetti A; Mailand D; Rubino S; Albrecht A; Huber J; Petraglia F; Genazzani AR
    J Endocrinol Invest; 1996 Sep; 19(8):535-41. PubMed ID: 8905477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Influence of estradiol administration mode on plasma insulin-like growth factor-I (IGF-I) and its binding proteins 1 and 3 concentration in postmenopausal women treated with norethisterone acetate].
    Milewicz T; Krzysiek J; Rogatko I; Sztefko K; Stochmal E; Hubalewska-Dydejczyk A; Jach R; Radowicki S
    Ginekol Pol; 2011 Mar; 82(3):200-4. PubMed ID: 21735688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects on the androgen status of postmenopausal women treated with tibolone and continuous combined estradiol and norethindrone acetate replacement therapy.
    Dören M; Rübig A; Coelingh Bennink HJ; Holzgreve W
    Fertil Steril; 2001 Mar; 75(3):554-9. PubMed ID: 11239541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin-like growth factors and IGF binding proteins 1 and 3: a cross-over study.
    Helle SI; Omsjø IH; Hughes SC; Botta L; Hüls G; Holly JM; Lønning PE
    Clin Endocrinol (Oxf); 1996 Dec; 45(6):727-32. PubMed ID: 9039339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation by progestogens of the effects of oestrogen on hepatic endocrine function in postmenopausal women.
    Nugent AG; Leung KC; Sullivan D; Reutens AT; Ho KK
    Clin Endocrinol (Oxf); 2003 Dec; 59(6):690-8. PubMed ID: 14974909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgenic progestogens oppose the decrease of insulin-like growth factor I serum level induced by conjugated oestrogens in postmenopausal women. Preliminary report.
    Campagnoli C; Biglia N; Lanza MG; Lesca L; Peris C; Sismondi P
    Maturitas; 1994 May; 19(1):25-31. PubMed ID: 7935029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transdermal sequential and continuous hormone replacement regimens with estradiol and norethisterone acetate in postmenopausal women: effects on the endometrium.
    Johannisson E; Holinka CF; Arrenbrecht S
    Int J Fertil Womens Med; 1997; 42 Suppl 2():388-98. PubMed ID: 9397386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The insulin-like growth factor-I system and hormone replacement therapy.
    Cardim HJ; Lopes CM; Giannella-Neto D; da Fonseca AM; Pinotti JA
    Fertil Steril; 2001 Feb; 75(2):282-7. PubMed ID: 11172828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of hormone replacement therapy on serum levels of tumor markers in healthy postmenopausal women.
    Cengiz B; Atabekoglu C; Cetinkaya E; Cengiz SD
    Maturitas; 2003 Dec; 46(4):301-6. PubMed ID: 14625127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of continuous combined estradiol-norethisterone acetate preparations on insulin sensitivity in postmenopausal nondiabetic women.
    Kimmerle R; Heinemann L; Heise T; Bender R; Weyer C; Hirschberger S; Berger M
    Menopause; 1999; 6(1):36-42. PubMed ID: 10100178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of effects of sequential transdermal administration versus oral administration of estradiol plus norethisterone acetate on serum NO levels in postmenopausal women.
    Kurtay G; Ozmen B; Erguder I
    Maturitas; 2006 Jan; 53(1):32-8. PubMed ID: 16325022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of norethisterone acetate addition to estradiol in long term HRT.
    Li C; Samsioe G; Wilaman K; Lidfelt J; Nerbrand C; Agardh CD; Schersten B
    Maturitas; 2000 Aug; 36(2):139-52. PubMed ID: 11006501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced androgen levels in adult turner syndrome: influence of female sex steroids and growth hormone status.
    Gravholt CH; Svenstrup B; Bennett P; Sandahl Christiansen J
    Clin Endocrinol (Oxf); 1999 Jun; 50(6):791-800. PubMed ID: 10468952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma insulin-like growth factor-I and its binding proteins 1 and 3 during continuous nonoral and oral combined hormone replacement therapy.
    Raudaskoski T; Knip M; Laatikainen T
    Menopause; 1998; 5(4):217-22. PubMed ID: 9872487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A potentially deleterious role of IGFBP-2 on bone density in aging men and women.
    Amin S; Riggs BL; Atkinson EJ; Oberg AL; Melton LJ; Khosla S
    J Bone Miner Res; 2004 Jul; 19(7):1075-83. PubMed ID: 15176989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Responses of HDL subclasses, Lp(A-I) and Lp(A-I:A-II) levels and lipolytic enzyme activities to continuous oral estrogen-progestin and transdermal estrogen with cyclic progestin regimens in postmenopausal women.
    Tilly-Kiesi M; Kahri J; Pyörälä T; Puolakka J; Luotola H; Lappi M; Lahdenperä S; Taskinen MR
    Atherosclerosis; 1997 Mar; 129(2):249-59. PubMed ID: 9105568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.